Pulmonary Hypertension – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder characterized by high blood pressure in the arteries of the lungs. The progressive condition is associated with significant morbidity and mortality. A wide array of drugs is available for PAH treatment in the U.S. market. The most commonly prescribed first-line treatments are phosphodiesterase-5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs), while more effective prostacyclin therapies are reserved for later lines. Branded therapies feature highly in the PAH treatment regimen, and polypharmacy is common. Additionally, Merck & Co.’s sotatercept (Winrevair) has shown promising results by significantly improving exercise capacity and reducing the risk of clinical worsening events, thereby offering a new therapeutic pathway for PAH patients. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated PAH patients receive pharmacotherapy in the United States.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
• How have Opsumit, Winrevair, Uptravi, Adempas, and Tyvaso / Tyvaso DPI been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of PAH patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of PAH patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: United Therapeutics, Actelion, Pfizer, Bayer, Gilead

Key drugs: Opsumit, Tyvaso, Tyvaso DPI, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, ambrisentan, bosentan, sildenafil, tadalafil, epoprostenol